ClinicalTrials.gg
Not yet recruitingNCT07368023Updated Jan 26, 2026

A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma

An observational study in Hepatocellular Carcinoma and Hepatocellular Carcinoma Non-resectable, sponsored by Ningbo Medical Center Lihuili Hospital. Not yet recruiting at 1 site in China. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Ningbo Medical Center Lihuili Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
300
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,314 studies in Carcinoma, Hepatocellular with a site in China — 489 open to participants now, 561 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
121st of 275
300 · median 300
Started
2026
with 97 others
Observational
275 of 1,314
120 open now
Primary completion
2026-01
later than 199 of 560 live
Registered
1,187th of 1,314
by date

Among the 1,314 studies in Carcinoma, Hepatocellular with a site in China, this one is the 121st largest by planned enrollment of the 275 observational ones that give a count, is one of 98 that started in 2026, is one of 275 observational ones, reaches primary completion later than 199 of the 560 other live ones, and was the 1,187th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

489 of the 1,314 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

484 more — sign in →

All 489 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,314 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary objective is to assess the outcomes of intention-to-treat (ITT) patients who received multidisciplinary conversion therapy. This therapy combines locoregional treatments (LRT, such as TACE or radiotherapy) with systemic therapy (anti-VEGF/tyrosine kinase inhibitors and immune checkpoint inhibitors) with the goal of down-staging tumors to allow for subsequent curative resection.

The study plans to enroll 300 subjects. The exposure group will include approximately 100 patients with initially unresectable HCC who received the combined conversion therapy between January 2018 and December 2024. A control group of about 200 patients with initially resectable HCC who underwent direct radical surgery during the same period will be used for comparison. Data will be collected retrospectively from hospital electronic medical records and the HCC clinical database, with follow-up until December 2025.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Hepatocellular Carcinoma Non-resectable
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This retrospective single-center cohort study includes 300 HCC patients (2018-2024), divided by initial resectability:

Initially Unresectable HCC Cohort(N=100): Received multimodal conversion therapy (LRT + anti-VEGF/TKIs + ICIs) aiming to downstage tumors for resection.

Initially Resectable HCC Cohort(N=200): Underwent direct radical resection without prior conversion therapy.

Patients were aged ≥16 with CNLC stage I-IIIA HCC. Exclusions: extrahepatic metastasis or Cheng's type IV PVTT/type II-III IVCTT. Data are collected retrospectively from EMR and an HCC database.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 16 years or older.
  • Clinical and/or pathological diagnosis of hepatocellular carcinoma (HCC). China Liver Cancer (CNLC) stage I, II, or IIIA.
  • Assessed by a multidisciplinary team (MDT) as having initially unresectable HCC.

Exclusion criteria

Exclusion Criteria:

  • Presence of extrahepatic .
  • Presence of Cheng's type IV portal vein tumor thrombus (PVTT).
  • Presence of Cheng's type II or III inferior vena cava tumor thrombus (IVCTT).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Initially Unresectable HCC with Conversion Therapy

    This cohort consists of patients with hepatocellular carcinoma (HCC) that was initially assessed as unresectable (due to surgical inoperability or oncological unresectability per multidisciplinary team evaluation) but intended for curative treatment. All patients in this cohort received multimodal conversion therapy between January 2018 and December 2024. The therapy aimed to downstage the tumor and primarily included a combination of locoregional therapies (LRT) (such as TACE, HAIC, or radiotherapy) and systemic drug therapy (including anti-VEGF/tyrosine kinase inhibitors and immune checkpoint inhibitors). Patient data are collected retrospectively from electronic medical records and the HCC clinical database.

    Combination Product: Locoregional Therapy (LRT) + Systemic Drug Therapy

  • Initially Resectable HCC

    This cohort consists of patients with hepatocellular carcinoma (HCC) that was initially assessed as resectable and suitable for curative surgery per multidisciplinary team evaluation. All patients in this cohort underwent direct radical resection (curative-intent surgery) as the primary treatment between January 2018 and December 2024, without receiving prior locoregional or systemic conversion therapy. Patient data are collected retrospectively from electronic medical records and the HCC clinical database.

Interventions

  • Combination productLocoregional Therapy (LRT) + Systemic Drug Therapy

    Treatment regimens, doses, and durations varied based on individual clinical decisions and are collected retrospectively.

06

What researchers measure

Primary outcomes

  1. Conversion Rate

    Proportion of ITT patients with initially unresectable HCC successfully down-staged to resectability after conversion therapy (per MDT reassessment).

    Time frame: From the start of conversion therapy until the completion of therapy (assessed up to 24 months).

  2. 1-, 2-, and 3-year OS in ITT Population

    Proportion of patients in the ITT population alive at 1, 2, and 3 years after initiation of conversion therapy (Kaplan-Meier method).

    Time frame: Starting from conversion therapy, evaluate at 1, 2, and 3 years.

  3. Resection Rate After Conversion

    Proportion of patients who successfully undergo curative resection after down-staging.

    Time frame: From the start of conversion therapy to the day of surgery (with a maximum evaluation period of 24 months).

07

Study locations

1 site
  • Ningbo Medical Centre Lihuili Hospital
    Ningbo, Zhejiang 315000, China
08

References and documents

Individual participant data

Plan to share: Undecided — A decision regarding the sharing of individual participant data (IPD) has not yet been made. The research team is currently assessing the feasibility, institutional policies, and ethical considerations related to data de-identification and sharing. A final plan will be determined prior to the completion of the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Jan 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Jan 26, 2026
StartEst.
Jan 25, 2026
Primary completionEst.
Jan 31, 2026
CompletionEst.
May 31, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07368023
Lead sponsor
Ningbo Medical Center Lihuili Hospital
Responsible party
Caide Lu (Chief Physician, Ningbo Medical Center Lihuili Hospital) — Principal investigator
First posted
Jan 26, 2026
Start date
Jan 25, 2026 (estimated)
Primary completion
Jan 31, 2026 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

Caide Lu, Professor
Contact
lucaide@nbu.edu.cn
+8613957800900
Shuqi Mao, Professor
Contact
mmmaoshuqi@163.com
+8617855848257
Caide Lu, Professor
principal investigator · Ningbo Medical Centre Lihuili Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion